Nkarta Therapeutics
CA - South SF
BiotechnologyFocus: Allogeneic cellular immunotherapy platform
Nkarta Therapeutics is a life sciences company focused on Allogeneic cellular immunotherapy platform.
ImmunologyOncologyCell Therapy
Open Jobs
1
Pipeline & Clinical Trials
NKX019
Lymphoma, Non-HodgkinClinical Trials (1)
NCT05020678NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Phase 1NKX101 - CAR NK cell therapy
Relapsed/Refractory AMLClinical Trials (1)
NCT04623944NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Phase 1NKX019
Lupus NephritisClinical Trials (1)
NCT06557265A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Phase 1/2NKX019
Systemic SclerosisClinical Trials (1)
NCT06733935A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Phase 1/2Open Jobs (1)
Interview Prep Quick Facts
Founded: 2017
Portfolio: 4 clinical trials
Open Roles: 1 active job
Hiring Trend
Stable
1
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles